Xenetic Biosciences’ (XBIO) “Neutral” Rating Reiterated at HC Wainwright

HC Wainwright reissued their neutral rating on shares of Xenetic Biosciences (NASDAQ:XBIO) in a research report released on Friday morning,Benzinga reports.

Xenetic Biosciences Stock Performance

Shares of XBIO opened at $4.04 on Friday. Xenetic Biosciences has a fifty-two week low of $2.78 and a fifty-two week high of $5.20. The stock has a fifty day moving average of $3.91 and a two-hundred day moving average of $3.92. The company has a market capitalization of $6.22 million, a PE ratio of -1.52 and a beta of 2.25.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.14). The business had revenue of $0.61 million during the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. As a group, equities research analysts forecast that Xenetic Biosciences will post -1.01 earnings per share for the current fiscal year.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.